Skip to main content

iShares U.S. Pharmaceuticals ETF (IHE)

NYSEARCA: IHE · IEX Real-Time Price · USD
186.43
+0.00 (0.00%)
After-hours:Oct 20, 2021 8:00 PM EDT
186.43
1.56 (0.84%)
At close: Oct 20, 4:00 PM
Assets$369.72M
NAV$184.86
Expense Ratio0.42%
PE Ratio22.72
Shares Out2.00M
Dividend (ttm)$2.71
Dividend Yield1.47%
Ex-Dividend DateSep 24, 2021
1-Year Return
-
Volume8,154
Open184.87
Previous Close184.88
Day's Range184.87 - 187.21
52-Week Low155.59
52-Week High198.62
Beta0.88
Holdings51
Inception DateMay 1, 2006

About IHE

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.

Asset ClassEquity
SectorBiotech
RegionNorth America
IssuerBlackRock iShares
Stock ExchangeNYSEARCA
Ticker SymbolIHE
Index TrackedDow Jones U.S. Select Pharmaceuticals Index

Top 10 Holdings

77.02% of assets
NameSymbolWeight
Johnson & JohnsonJNJ22.42%
PfizerPFE18.51%
MerckMRK4.96%
ZoetisZTS4.59%
Royalty PharmaRPRX4.58%
Elanco Animal HealthELAN4.53%
Eli LillyLLY4.47%
CatalentCTLT4.40%
ViatrisVTRS4.39%
Bristol-Myers SquibbBMY4.17%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 24, 2021$0.832Sep 30, 2021
Jun 10, 2021$0.72063Jun 16, 2021
Mar 25, 2021$0.63484Mar 31, 2021
Dec 14, 2020$0.5261Dec 18, 2020
Sep 23, 2020$0.70888Sep 29, 2020
Jun 15, 2020$0.31386Jun 19, 2020
Full Dividend History

News

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.

Other symbols:GERMGNOMVIRSXHE
1 month ago - Zacks Investment Research

Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols:FTXHPJPPPHXPH
2 months ago - Zacks Investment Research

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

2 months ago - Zacks Investment Research

5 Sector ETFs That Survived Last Week's Turmoil

We have highlighted five sector ETFs that performed well last week and survived the broad market rout.

Other symbols:BUGPSCCRING
5 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q1 Earnings

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:FTXHPJPPPHXPH
5 months ago - Zacks Investment Research

Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause

Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...

Other symbols:BBHFHLCIEIH
6 months ago - ETF Trends

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols:FDLFTXHIEIH
6 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols:FTXHPJPPPHXPH
8 months ago - Zacks Investment Research

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:FTXHPJPPPHXPH
11 months ago - Zacks Investment Research

Best Pharmaceutical ETFs for Q1 2021

The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.

Other symbols:KUREXPH
11 months ago - Investopedia

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other symbols:CNBSGNOMIHFIHIPJPXHE
11 months ago - Zacks Investment Research

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols:FTXHPJPPPHXPH
1 year ago - Zacks Investment Research

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

1 year ago - Zacks Investment Research

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Other symbols:FTXHPJPPPHXPH
1 year ago - Zacks Investment Research

Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

Other symbols:FTXHPJPPPHXPH
1 year ago - Zacks Investment Research

JNJ Beats, Ups View: Healthcare ETFs to Buy

Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.

Other symbols:IEIHIYHVHTXLV
2 years ago - Zacks Investment Research

Johnson & Johnson, UnitedHealth Give Healthcare ETFs a Much Needed Bolster Shot

Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much...

Other symbols:IHFXLV
2 years ago - ETF Trends

Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

Other symbols:FTXHPJPPPHXPH
2 years ago - Zacks Investment Research

Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat

Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.

Other symbols:IEIHIYHVHTXLV
2 years ago - Zacks Investment Research

Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

Other symbols:FTXHPJPPPHXPH
2 years ago - Zacks Investment Research